I20-I25, I27, I30-I52), cerebrovascular diseases (I60-I69), pneumonia (J12-J18), accidents (V01-X59), suicide (X60-X84), senility (R54), renal failure (N17-N19), liver diseases (K70-K77) and (COPD) (J41-J44).
Data on annual wholesales of statins in the 47 prefectures of Japan were provided by Crecon Research and Consulting Incorporation (Tokyo), a company which performs marketing surveys. The population in each 47 prefectures based on 5-year-age range was obtained from the data by the Statistics Bureau Ministry of Internal Affairs and Communications in Japan
The statistical analysis of correlation was performed using StatView-J5.0 (Abacus Concepts, Inc., Berkeley, CA, USA) and the level of significance was set at p < 0.05.
RESULTS
We show only the results from the 2003 data available on statin sales and the major causes of death in Japan, because we had obtained similar results from the data on each of the three years surveyed, 2001, 2002 and 2003 . Table 1 shows the mortalities from the top ten causes of death in the 47 prefectures in 2003. These were malignancy, heart diseases except for hypertension, cerebrovascular diseases, pneumonia, accidents, suicide, senility, renal failure, liver diseases and COPD. Each of the prefecture-based statin sales and statin sales per capita in the aged population in 2003 are shown in the Table 2 .
Based on the data of Table 1 and 2, we analyzed the relationships between the mortalities from the major death causes and the annual statin sales per capita in the 47 prefectures. As shown in Fig. 1 , the annual statin sales significantly and negatively correlated with mortalities from COPD (Fig. 1K , p < 0.0001), senility (Fig. 1H , p = 0.002), all causes (Fig. 1A , p = 0.017), pneumonia (Fig.  1E , p = b0.018), cerebrovascular diseases (Fig.  1D , p = 0.024), accidents (Fig. 1F , p = 0.034), and heart diseases except hypertension (Fig. 1C , p = 0.039). However, there was no correlation with renal failure (Fig. 1I , p = 0.102), liver diseases (Fig. 1J , p = 0.180), suicide (Fig. 1G , p = 0.393) and malignancy (Fig. 1B , p = 0.409).
ing cholesterol levels but also by their pleotropic effects such as anti-inflammatory and anti-oxidant effects (Calabro and Yeh 2005; Lahera et al. 2007 ). There have been many clinical reports demonstrating that treatment with statins prevents primary and secondary cardiovascular events as well as reduction of mortality from cardiovascular diseases (Evans et al. 2004; Baigent et al. 2005) . In addition to the effect of statins on atherosclerotic diseases, it may be possible that statins also suppress other diseases such as inflammatory diseases by their pleiotropic effects.
In order to observe population-based effects of statin use on cardiovascular and other diseases, we analyzed relationships between statin sales (as a marker of statin use) per capita in aged population of more than 65 years and the mortalities from major causes of death in different districts in Japan. The analysis was performed by using data obtained from marketing surveys on statin sales and government reports on the mortalities such as malignancy, heart diseases except hypertension, cerebrovascular diseases, pneumonia, accidents, suicide, senility, renal failure, liver diseases and chronic obstructive pulmonary disease (COPD) (Ministry of Health, Labour and Welfare, Japan) in the 47 prefectures of Japan.
There were significant negative correlations between statin sales and mortalities from cardiovascular diseases ( p < 0.05) as expected. In addition, we unexpectedly found that there were strongly negative correlations between statin sales and mortalities from COPD ( p < 0.0001), senility ( p < 0.01), pneumonia ( p < 0.05), accidents ( p < 0.05), and all death causes ( p < 0.05). 
MATERIALS AND METHODS

Data
DISCUSSION
We analyzed population-based relationships between statin sales, as a marker of statin use, and mortalities from major death causes in 47 prefectures in Japan in order to observe the possible effects of statins on various diseases. The data on mortalities, obtained from the government annual reports (MHLW, Japan), were based on the death certificates written by the attending physicians and these had been sent to the municipal offices in Japan.
Among the class of HMG-CoA reductase inhibitors (statins), pravastatin, simvastatin, atrovastatin, fluvastatin and their generics were commercially available during the period from 2001-2003 in Japan. However due to the fact that there were no available data on the number of patients regularly taking statins or on the number of prescriptions of statins in each prefecture, we instead utilized prefecture-based statin wholesales in Japan. Monthly surveys on wholesales of statins and their generics sold by wholesalers of medicines in the prefectures of Japan were provided to us by a company performing these surveys.
We analyzed the relationship between statin sales and mortalities only in the population aged more than 65 years due to the fact that most of the top ten death causes were diseases associated with the aged population in Japan, where the life expectancy was 78.4 years in males and 85.3 years in females in 2003 (Statistics Bureau & Statistical Research and Training Institute, Japan) , and also because statins were taken by patients from middle to old age in Japan (Segawa et al. 2004) . The correlations between statin sales per capita and mortalities were most significant in this population (> 65-year old) in the preliminary analysis.
The We expected that statin sales would be negatively correlated with mortality from cardiovascular diseases, because it has already been reported that statins reduce cardiovascular events and mortality from these diseases in clinical trials (LaRosa 2002) . As expected, statin sales per capita was significantly associated with a lower mortality from heart diseases except hypertension (Fig. 1C ) and cerebrovascular diseases (Fig. 1D ). Statin sales also had a significantly negative association with mortality from senility which is associated with aging. The aging process is complex, however, mortality from senility may partly be due to oxidative stress and inflammation (McEwen et al. 2005; Capri et al. 2006) , which may possibly be protected by statins.
On the other hand, we unexpectedly found that statin sales negatively correlated with pulmonary diseases such as COPD (Fig. 1K ) and pneumonia (Fig. 1E ). This negative correlation was especially strong with COPD ( p < 0.0001) (Fig.  1K) . Mancini et al. (2006) recently reported the reduction of cardiovascular events and COPD hospitalization by combination therapy with statins and angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) by the time-matched nested case-control study of population-based retrospective cohorts and implied the beneficial effects of statins on COPD. More recently it has been reported by Soyseth et al. (2007) using a retrospective cohort design that treatment with statins was associated with improved survival after COPD exacerbation regardless of inhaled corticosteroids. Although the pathogenesis of COPD is unknown (Barnes 2000) , oxidative stress has been implicated (Molfino and Jeffery 2006; Rahman and Kilty 2006) . Pleiotropic activities of statins including anti-oxidative and anti-inflammatory effects (Calabro and Yeh 2005; Lahera et al. 2007 ) may protect pulmonary damage (Mancini et al. 2006; Morimoto et al. 2006) . Taken together, the previous reports (Mancini et al. 2006; Soyseth et al. 2007) , it would be worthwhile to perform randomized clinical trials to confirm the beneficial effects of statins on pulmonary diseases, especially Abbrevaiation: HD, heart diseases except hypertension; CVD, cerebrovascular disease; COPD, chronic obstructive pulmonary disease
The data were obtained from http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai03/toukei9.html COPD, because such data have not been reported yet.
There was a negative correlation between statin sales and accidents (Fig. 1F) , which included transport accidents and other external causes of accidental injury (ICD-10, V01-X59). However, this data should be interpreted carefully, because the populations that died of accidents were younger rather than older and the analysis was done in the aged population. Statin sales was not associated with mortalities from renal failure (Fig.  1I ) and liver diseases (Fig. 1J) by any causes. The use of statins also did not correlate with mortality from suicide (Fig. 1G) , and this is consistent with recent reports (Gurm and Hoogwerf 2003; Yang et al. 2003) , although there have been debates on this issue. There was no relationship between statin sales and malignancy (Fig. 1B) as previously indicated (Hebert et al. 1997; Dale et al. 2006 ). Due to the fact that these diseases except for malignancy affected relatively younger ages, the association analyses of these diseases with statin sales in the aged population may be meaningless in this analysis.
Interestingly, one extreme exception in the correlation between statin sales and the mortalities was in Okinawa prefecture, where mortalities from cerebrovascular diseases, cardiovascular diseases (heart diseases except hypertension), and all other causes were lowest regardless of having the lowest statin sales (Fig. 1A, 1C and 1D) . Okinawa is an island of longevity, where cardiovascular risk factors are fewer because of traditional healthy food cultures (Suzuki et al. 2001; Tatsukawa et al. 2004 ).
There was no positive correlation between statin sales and mortalities from major causes of death, implying that there were no populationbased life-threatening adverse effects with the use of statins. On the contrary, mortality from all causes of death was negatively associated with statin sales, indicating overall beneficial effects of statins on mortalities (Baigent et al. 2005) .
Finally, although possible beneficial effects of statins on various diseases are implied in this paper, there are limitations in this study, because the study is a population-based comparison between statin sales per capita, as a marker of statin use, and mortalities from major death cause. There may be potential confounding factors such as sufficient medical care, and use of ACE, ARB, anti-platelet agents, corticosteroids, and thiazolidinediones especially in association of statin sales with reduced mortality rate in COPD. However, it is not possible to analyze such confounding factors in our study because of population-based study, but not case-control study. Therefore, a prospective study is necessary to confirm a possible protective effect of statins especially on COPD.
